<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02927353</url>
  </required_header>
  <id_info>
    <org_study_id>DMB-3113-1</org_study_id>
    <nct_id>NCT02927353</nct_id>
  </id_info>
  <brief_title>A Phase 1 Pharmacokinetic Bioequivalence Study of DMB-3113 and Adalimumab in Healthy Japanese Adult Male Subjects</brief_title>
  <acronym>DMB-3113-1</acronym>
  <official_title>A Phase 1 Pharmacokinetic Bioequivalence Study of DMB-3113 and Adalimumab in Healthy Japanese Adult Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Meiji Seika Pharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Meiji Seika Pharma Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the pharmacokinetic bioequivalence of DMB-3113 and adalimumab and to confirm the
      safety of the study drug in healthy Japanese adult male subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Actual">January 17, 2017</completion_date>
  <primary_completion_date type="Actual">January 17, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the serum concentration-time curve (AUC) from 0 to final sampling time point</measure>
    <time_frame>Day 1 to Day 71</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC from 0 to infinity</measure>
    <time_frame>Day 1 to Day 71</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum serum concentration (Cmax)</measure>
    <time_frame>Day 1 to Day 71</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC from 0 to the last measurable concentration</measure>
    <time_frame>Day 1 to Day 71</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach the peak concentration (tmax)</measure>
    <time_frame>Day 1 to Day 71</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean residence time (MRT) from 0 to final sampling time point</measure>
    <time_frame>Day 1 to Day 71</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRT from 0 to infinity</measure>
    <time_frame>Day 1 to Day 71</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination rate constant (kel)</measure>
    <time_frame>Day 1 to Day 71</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination half life (t1/2)</measure>
    <time_frame>Day 1 to Day 71</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed clearance (CL/F)</measure>
    <time_frame>Day 1 to Day 71</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed volume of distribution (V/F)</measure>
    <time_frame>Day 1 to Day 71</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Day 1 to Day 71</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">180</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>DMB-3113</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>adalimumab biosimilar</description>
  </arm_group>
  <arm_group>
    <arm_group_label>adalimumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>adalimumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DMB-3113</intervention_name>
    <description>subcutaneously injected in a single dose of 40 mg.</description>
    <arm_group_label>DMB-3113</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adalimumab</intervention_name>
    <description>subcutaneously injected in a single dose of 40 mg.</description>
    <arm_group_label>adalimumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy Japanese male adults;

          2. The Body Mass Index (BMI) of the subjects must be from 17.6 to 26.4 kg/m2 at the time
             of the screening test;and

          3. Subjects must take a screening test within the 4 weeks before the date of
             administration of the study drug; subjects must take a screening test before the date
             of administration of the study drug and exhibit no clinically abnormal findings in the
             judgment of the investigator or any of the subinvestigators

        Exclusion Criteria:

          1. Concurrent or history of potentially fatal infections such as opportunistic
             infections, including sepsis, pneumonia, and fungal infection;

          2. Individuals with history of tuberculosis or diagnosed with tuberculosis by interview,
             chest X-ray examination, or interferon-gamma release assay;

          3. Concurrent or history of demyelinating disease (multiple sclerosis, etc.);

          4. Concurrent or history of congestive cardiac failure;

          5. Concurrent or history of allergic symptoms such as asthma bronchial, drug-induced
             rash, and urticaria, which, in the judgment of the investigator or any of the
             subinvestigators, may affect participation in this clinical study; or

          6. Concurrent or history of cardiac, hepatic, renal, gastrointestinal, respiratory,
             and/or hematological function disorders, which, in the judgment of the investigator or
             any of the subinvestigators, may affect participation in this clinical study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hideki Fushimi, Manager</last_name>
    <role>Study Director</role>
    <affiliation>Meiji Seika Pharma Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2016</study_first_submitted>
  <study_first_submitted_qc>October 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2016</study_first_posted>
  <last_update_submitted>August 17, 2017</last_update_submitted>
  <last_update_submitted_qc>August 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bioequivalence, Biosimilarity, Pharmacokinetics, adalimumab</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

